Skip to main content

Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea

Periodic Reporting for period 1 - Nyxoah (Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea)

Reporting period: 2016-06-01 to 2016-09-30

Nyxoah project aims to introduce to the market a tiny HypoGlossal Nerve Stimulation (HGNS) system for the treatment of moderate to severe OSA patients who are not compliant with CPAP therapy. The key objectives of the project are to gather sufficient clinical evidence to commercialise the system as a CE certified medical device in Europe.
During the Phase 1 Feasibility Assessment, Nyxoah accomplished a full analysis of the business potential of the Nyxoah’s GenioTM. Throughout the duration of the project, Nyxoah increased its knowledge of the medical device market, including regulations, medical device reimbursement standards, market size and competitors.
In the feasibility study, Nyxoah estimated that there are around 4.6 million OSA sufferers in Europe who need an alternative solution to treat this sleep disorder breathing. Nyxoah decided to primarily target already diagnosed patients who are non-compliant with CPAP (700K) or refuse CPAP (100K), sizing the potential market at 800K patients.
Nyxoah’s disruptive technology will promote health and wellbeing, and improve patient quality of life. Nyxoah proposes an innovative OSA treatment for patients and sleep specialists. Nyxoah’s GenioTM will offer a minimally invasive, effective and easy-to-use OSA alternative therapy to millions of OSA sufferers and thousands of sleep specialists.
Nyxoah’s GenioTM implant
Nyxoah’s GenioTM patch
Nyxoah’s GenioTM